# US 2021/0171655 A1 · Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171655 A1
- Document ID: US20210171655A1
- Status: Published application
- Kind: A1
- Application number: 17/093,474
- Filed: 2020-11-09
- Published: 2021-06-10
- Earliest claimed: 2010-06-15
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Thomas J. KIPPS; Jianqianq Yu
- Web page: https://patentgrep.com/patent/US20210171655A1

## CPC

- C07K 16/30: from tumour cells
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 16/40: against enzymes
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.

## Claims

### Claim at position 1

-37. (canceled)

### Claim 38

A nucleic acid encoding a polypeptide comprising a single-chain variable fragment (scFv) comprising:
a light chain variable region that comprises a CDR L1 corresponding to amino acid position 27-32 of SEQ ID NO: 2, a CDR L2 corresponding to amino acid position 50-52 of SEQ ID NO: 2, and a CDR L3 corresponding to amino acid position 89-97 of SEQ ID NO: 2; and
a heavy chain variable region that comprises a CDR H1 corresponding to amino acid position 151-158 of SEQ ID NO: 2, a CDR H2 corresponding to amino acid position 176-182 of SEQ ID NO: 2, and a CDR H3 corresponding to amino acid position 223-233 of SEQ ID NO: 2, wherein said scFv is capable of binding receptor tyrosine kinase-like orphan receptor 1 (ROR1).

### Claim 39 (depends on 38)

The nucleic acid of claim 38, wherein said polypeptide is a chimeric antigen receptor.

### Claim 40 (depends on 39)

The nucleic acid of claim 39, wherein said chimeric antigen receptor is humanized.

### Claim 41 (depends on 38)

The nucleic acid of claim 38, wherein said polypeptide is an antibody or antigen binding fragment thereof.

### Claim 42 (depends on 41)

The nucleic acid of claim 41, wherein said antibody is humanized.

### Claim 43 (depends on 38)

The nucleic acid of claim 38, wherein said polypeptide comprises an Fc region from an antibody.

### Claim 44 (depends on 43)

The nucleic acid of claim 43, wherein said Fc region is a human Fc region.

### Claim 45 (depends on 38)

The nucleic acid of claim 38, wherein said nucleic acid is a component of an expression vector.

### Claim 46 (depends on 45)

The nucleic acid of claim 45, wherein said expression vector is a viral vector.

### Claim 47 (depends on 46)

The nucleic acid of claim 46, wherein said viral vector is a lentivirus
